Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flecainide inhalation - InCarda Therapeutics

Drug Profile

Flecainide inhalation - InCarda Therapeutics

Alternative Names: Flecainide acetate inhalation solution; FlecIH-101; FlecIH-103; FlecIH-104; Inhaled flecainide - InCarda Therapeutics; InRhythm™

Latest Information Update: 19 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InCarda Therapeutics
  • Class Benzamides; Class Ic antiarrhythmics; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Paroxysmal atrial fibrillation

Most Recent Events

  • 09 Jun 2023 InCarda Therapeutics terminates the Phase-III RESTORE-1 clinical trial in Paroxysmal atrial fibrillation (Newly diagnosed) in USA, Spain, Poland, Hungary, Czech Republic, Netherlands (Inhalation, Liquid) due to limited efficacy upon blinded review (NCT05039359) (EudraCT2021-001627-40)
  • 12 Dec 2022 Phase-I development is ongoing in Australia for Paroxysmal atrial fibrillation (In volunteers) (Inhalation) (ACTRN12620000461998)
  • 26 Aug 2022 Efficacy data from a phase II trial in Paroxysmal atrial fibrillation presented at theannual congress of the European Society of Cardiology (ESC-Card-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top